US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

• Source: Shutterstock

High demand for OTC cough/cold and pain relief remedies in the US and Canada almost certainly point to consumer health firms reporting strong sales growth in the most recent quarter, with results for the Vicks line the first barometer as Procter & Gamble is first out of the sales-and-earnings gate.

US and Canadian firms marketing OTC drug and dietary supplement and reporting results for the October-December period also will be offering additional signals on planned spinoffs of their consumer health business, in the case of Johnson &

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business